Trial Profile
Phase II trial of vaccination with lysate-loaded, mature dendritic cells integrated into standard radiochemotherapy in newly diagnosed glioblastoma - GlioVax
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 26 Dec 2022
Price :
$35
*
At a glance
- Drugs GlioVax (Primary)
- Indications Glioblastoma
- Focus Therapeutic Use
- Acronyms GlioVax
- 22 Dec 2022 Planned End Date changed from 6 Jun 2023 to 6 Jun 2025.
- 22 Dec 2022 Planned primary completion date changed from 6 Sep 2022 to 6 Sep 2024.
- 08 May 2018 Planned End Date changed from 6 Apr 2023 to 6 Jun 2023.